Associations of the Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer - Original Article

Sep 22, 2026

Genetic variants of deregulated long noncoding RNAs contribute to tumorigenesis, progression, and recurrence, yet the role of CDKN2B-AS1 in prostate cancer remains insufficiently clarified. This case–control study assessed CDKN2B-AS1 expression levels and variants in 695 prostate cancer patients and 695 healthy controls. The rs1333048 minor C allele increased tumor risk and associated high Gleason grades, especially without biochemical recurrence. Bioinformatic and cellular analyses supported higher CDKN2B-AS1 expression with the C allele and links to aggressive clinical features, suggesting a mechanism accelerating progression.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages13

Reading Time33 min

AccessFree to download

Abstract

Introduction

Journal of Cellular and Molecular Medicine ORIGINAL ARTICLE OPEN ACCESS Associations ofthe Expression Levels and Risk Variants of CDKN2B-AS1 Long Noncoding RNA With the Susceptibility and Progression of Prostate Cancer Min-Che Tung1,2 | Chia-Yen Lin3,4,5 | Yu-Ching Wen6,7 | Lun-Ching Chang8 | Shun-Fa Yang9,10 | Ming-Hsien Chien2,11,12,13 1Division of Urology, Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan | 2Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan | 3Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan | 4School of Medicine, Chung Shan Medical University, Taichung, Taiwan | 5School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan | 6Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan | 7Department of Urology, School of Medicine, College of Medicine and TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei, Taiwan | 8Department of Mathematical Sciences, Florida Atlantic University, Florida, USA | 9Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan | 10Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan | 11Pulmonary Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan | 12Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, Taiwan | 13TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan Correspondence: Shun-Fa Yang ([ysf@csmu.edu.tw](ysf@csmu.edu.tw)) | Ming-Hsien Chien ([mhchien1976@gmail.com](mhchien1976@gmail.com)) Received: 29 October 2024 | Revised: 20 November 2024 | Accepted: 23 November 2024 Funding: This work was supported by Wan Fang Hospital, 113-wf-swf-05. Keywords: cancer progression | cancer susceptibility | cyclin-dependent kinase inhibitor 2B antisense RNA 1 | long noncoding RNA | prostate cancer | single-nucleotide polymorphism ABSTRACT Genetic variants of deregulated long noncoding RNAs (lncRNAs) have been implicated in tumorigenesis, cancer progression and cancer recurrence. Single-nucleotide polymorphisms (SNPs) of the lncRNA cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) have been associated with the risk and progression of various cancers; however, their role in prostate cancer (PCa) remains underexplored. In this case–control study, we investigated the associations of CDKN2B-AS1 expression levels and variants with PCa risk and progression. For this, five SNPs of CDKN2B-AS1—rs564398, rs1333048, rs1537373, rs2151280 andrs8181047—were genotyped using a TaqMan allelic discrimination assay; data were collected from 695 patients with PCa and 695 healthy controls. Our findings revealed that, under a dominant model, patients with PCa carrying at least one minor C allele of rs1333048 exhibited an increased risk of developing tumours with high Gleason grades; this risk was particularly high in patients without biochemical recurrence. Data from the Genotype-Tissue Expression database indicated upregulated CDKN2B-AS1 expression in the prostates of individuals carrying the polymorphic C allele of rs1333048 . Genotype screening of rs1333048 in PCa cell lines showed that cells with at least one minor C allele had higher CDKN2B-AS1 levels than those with the AA genotype. Furthermore, data from The Cancer Genome Atlas indicated that higher CDKN2B-AS1 levels in PCa tissues were correlated with larger tumour sizes (T3 + T4), more lymph node metastasis (N1), higher Gleason scores and shorter progression-free survival. In conclusion, the polymorphic variants of CDKN2B-AS1 at rs1333048 may modulate CDKN2B-AS1 expression, thus accelerating PCa progression. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any

FAQs

What was the main purpose of the study?

To evaluate whether CDKN2B-AS1 expression levels and genetic risk variants are associated with prostate cancer susceptibility and progression.

Which genetic variant showed an increased risk association in prostate cancer patients?

Under a dominant model, carriers of at least one minor C allele of rs1333048 had an increased risk of developing tumors with high Gleason grades.

How did higher CDKN2B-AS1 expression relate to clinical outcomes?

Higher CDKN2B-AS1 levels correlated with larger tumor sizes, lymph node metastasis, higher Gleason scores, and shorter progression-free survival.

Sep 22, 2026

Upload by Clementine